Abstract
The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for 12 weeks. Blood pressure (BP), plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen activities were evaluated at baseline and during treatment. The patients underwent a euglycemic-hyperinsulinemic clamp (insulin sensitivity was evaluated as glucose infusion rate during the last 30 min) and a desmopressin test (with desmopressin infusion in the brachial artery) to evaluate endothelial ability to release t-PA. Imidapril and candesartan induced similar systolic/diastolic BP reductions (16/12.6 and 16.1/12.2 mm Hg, respectively, P-1 per kg, P-1, P-1) than by candesartan (2.73 IU ml -1, P
| Original language | English |
|---|---|
| Pages (from-to) | 509-515 |
| Number of pages | 7 |
| Journal | Hypertension Research |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2011 |
Fingerprint
Keywords
- candesartan
- fibrinolysis
- imidapril
- insulin sensitivity
ASJC Scopus subject areas
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine
Cite this
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. / Fogari, Roberto; Zoppi, Annalisa; Salvadeo, Sibilla A T; Mugellini, Amedeo; Lazzari, Pierangelo; Santoro, Tara; Derosa, Giuseppe.
In: Hypertension Research, Vol. 34, No. 4, 04.2011, p. 509-515.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension
AU - Fogari, Roberto
AU - Zoppi, Annalisa
AU - Salvadeo, Sibilla A T
AU - Mugellini, Amedeo
AU - Lazzari, Pierangelo
AU - Santoro, Tara
AU - Derosa, Giuseppe
PY - 2011/4
Y1 - 2011/4
N2 - The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for 12 weeks. Blood pressure (BP), plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen activities were evaluated at baseline and during treatment. The patients underwent a euglycemic-hyperinsulinemic clamp (insulin sensitivity was evaluated as glucose infusion rate during the last 30 min) and a desmopressin test (with desmopressin infusion in the brachial artery) to evaluate endothelial ability to release t-PA. Imidapril and candesartan induced similar systolic/diastolic BP reductions (16/12.6 and 16.1/12.2 mm Hg, respectively, P-1 per kg, P-1, P-1) than by candesartan (2.73 IU ml -1, P
AB - The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for 12 weeks. Blood pressure (BP), plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen activities were evaluated at baseline and during treatment. The patients underwent a euglycemic-hyperinsulinemic clamp (insulin sensitivity was evaluated as glucose infusion rate during the last 30 min) and a desmopressin test (with desmopressin infusion in the brachial artery) to evaluate endothelial ability to release t-PA. Imidapril and candesartan induced similar systolic/diastolic BP reductions (16/12.6 and 16.1/12.2 mm Hg, respectively, P-1 per kg, P-1, P-1) than by candesartan (2.73 IU ml -1, P
KW - candesartan
KW - fibrinolysis
KW - imidapril
KW - insulin sensitivity
UR - http://www.scopus.com/inward/record.url?scp=79953680485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953680485&partnerID=8YFLogxK
U2 - 10.1038/hr.2010.260
DO - 10.1038/hr.2010.260
M3 - Article
C2 - 21179101
AN - SCOPUS:79953680485
VL - 34
SP - 509
EP - 515
JO - Hypertension Research
JF - Hypertension Research
SN - 0916-9636
IS - 4
ER -